High serum levels of IGF-I and IGFBP3 may increase comorbidity risk for asthmatic patients

Basit Öğe Kaydı
dc.authoridAcat, Murat/0000-0002-7163-4882
dc.authoridAyada, Ceylan/0000-0002-6272-4173
dc.contributor.authorAcat, M.
dc.contributor.authorErbay, Toru U.
dc.contributor.authorSahin, S.
dc.contributor.authorArik, O.
dc.contributor.authorAyada, C.
dc.date.accessioned2024-09-29T16:08:29Z
dc.date.available2024-09-29T16:08:29Z
dc.date.issued2017
dc.departmentKarabük Üniversitesien_US
dc.description.abstractOBJECTIVE: Asthma is known as a chronic inflammatory lung disease which has also systemic features. Insulin-like growth factor I (IGF-I) plays a role for asthma pathogenesis. Controversially, IGF-binding protein 3 (IGFBP3) blocks asthma development. That is why IGF-I and IGFBP3 are targeted for future therapeutic treatments of asthma. We aimed to investigate serum level of IGF-I and IGFBP3 in patients with asthma. This study was performed in 27 asthma and 23 healthy individuals. Serum levels of IGF-I and IGFBP3 were measured by human ELISA assay kits. Serum levels of IGF-I and IGFBP3 were significanlty higher in the asthma group than the control group. Significant negative correlation was found between IGF-I and asthma control test (ACT) puan, O-2 saturation, Forced Expiratory Volume in 1 second/ Forced Vital Capacity (FEV1/FVC), Forced Expiratory Flow 25 second/75 second (FEF2575) (%). Significant positive correlation was found between IGFBP3 and IGF-I, systolic blood pressure. Significant negative correlation was found between IGF-I and FEV1 (ml). RESULTS: Our results indicate that the serum levels of IGF-I and IGFBP3 are significanlty elevated in the asthma group. We assume that current treatment strategies are not really good enough for asthma. We suppose further strategies which are seeking to balance IGF-I and IGFBP3 should be developed for more effective and curative treatment of asthma (Tab. 2, Fig. 2, Ref. 22). Text in PDF www.elis.sk.en_US
dc.description.sponsorshipDumlupinar University [2013/15]en_US
dc.description.sponsorshipThis study was supported by Dumlupinar University Research Fund (Project No: 2013/15).en_US
dc.identifier.doi10.4149/BLL_2017_130
dc.identifier.endpage694en_US
dc.identifier.issn0006-9248
dc.identifier.issn1336-0345
dc.identifier.issue11en_US
dc.identifier.pmid29216726en_US
dc.identifier.scopus2-s2.0-85037624496en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage691en_US
dc.identifier.urihttps://doi.org/10.4149/BLL_2017_130
dc.identifier.urihttps://hdl.handle.net/20.500.14619/7574
dc.identifier.volume118en_US
dc.identifier.wosWOS:000418020700008en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherComenius Univen_US
dc.relation.ispartofBratislava Medical Journal-Bratislavske Lekarske Listyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectinsulin-like growth factor I (IGF-I)en_US
dc.subjectIGF-binding protein 3 (IGFBP3)en_US
dc.subjectasthmaen_US
dc.titleHigh serum levels of IGF-I and IGFBP3 may increase comorbidity risk for asthmatic patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu